Journal
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 23, Issue 10, Pages 3356-3358Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfn423
Keywords
acute interstitial nephritis; deferasirox; iron chelation
Categories
Ask authors/readers for more resources
Deferasirox is a new oral iron chelator used to treat transfusional iron overload. Pre-marketing clinical trials revealed little organ-specific toxicity. Increases in serum creatinine were noted in one-third of patients but were mild and non-progressive. We describe a 62-year-old man with myelodysplastic syndrome who developed a progressive decline in renal function after starting deferasirox. A kidney biopsy showed acute interstitial nephritis with increased eosinophils, suggesting drug hypersensitivity. Deferasirox was discontinued and renal function returned to baseline. This is the first pathological description of deferasirox-related acute kidney injury in humans, which differs from tubular vacuolization observed in animals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available